ESTRO meets Asia 2024 - Abstract Book

S93

Interdisciplinary – CNS

ESTRO meets Asia 2024

Keywords: brain metastases, local irradiation, tumor control

References:

1. Horbinski C, Nabors LB, Portnow J, Baehring J, Bhatia A, Bloch O , et al. NCCN Guidelines® Insights: Central Nervous System Cancers, Version 2.2022. J Natl Compr Canc Netw 2023;21:12-20. doi: 10.6004/jnccn.2023.0002.

2. Brennan C, Yang TJ, Hilden P, Zhang Z, Chan K, Yamada Y , et al. A phase 2 trial of stereotactic radiosurgery boost after surgical resection for brain metastases. Int J Radiat Oncol Biol Phys 2014;88:130-136. doi: 10.1016/j.ijrobp.2013.09.051. 3. Kocher M, Soffietti R, Abacioglu U, Villà S, Fauchon F, Baumert BG , et al. Adjuvant whole-brain radiotherapy versus observation after radiosurgery or surgical resection of one to three cerebral metastases: results of the EORTC 22952-26001 study. J Clin Oncol 2011;29:134-141. doi: 10.1200/jco.2010.30.1655. 4. Aoyama H, Shirato H, Tago M, Nakagawa K, Toyoda T, Hatano K , et al. Stereotactic radiosurgery plus whole-brain radiation therapy vs stereotactic radiosurgery alone for treatment of brain metastases: a randomized controlled trial. Jama 2006;295:2483-2491. doi: 10.1001/jama.295.21.2483. 5. Bostel T, Akbaba S, Wollschläger D, Mayer A, Nikolaidou E, Murnik M , et al. Chemoradiotherapy in geriatric patients with squamous cell carcinoma of the esophagus: Multi-center analysis on the value of standard treatment in the elderly. Front Oncol 2023;13:1063670. doi: 10.3389/fonc.2023.1063670. 6. Loesch D, Robert N, Jones S, Elkordy M, Ilegbodu D, Asmar L. Phase II Trial of a Novel Paclitaxel Schedule As Single-Agent, First-Line Therapy for HER-2/neu-Negative Metastatic Breast Cancer: A Community-Based Study. J Oncol Pract 2006;2:268-273. doi: 10.1200/jop.2006.2.6.268. 7. van Loon J, Grutters J, Wanders R, Boersma L, Oellers M, Dingemans AM , et al. Follow-up with 18FDG-PET-CT after radical radiotherapy with or without chemotherapy allows the detection of potentially curable progressive disease in non-small cell lung cancer patients: a prospective study. Eur J Cancer 2009;45:588-595. doi: 10.1016/j.ejca.2008.10.017. 8. Miyawaki E, Kenmotsu H, Mori K, Harada H, Mitsuya K, Mamesaya N , et al. Optimal Sequence of Local and EGFR TKI Therapy for EGFR-Mutant Non-Small Cell Lung Cancer With Brain Metastases Stratified by Number of Brain Metastases. Int J Radiat Oncol Biol Phys 2019;104:604-613. doi: 10.1016/j.ijrobp.2019.02.051. 9. Magnuson WJ, Yeung JT, Guillod PD, Gettinger SN, Yu JB, Chiang VL. Impact of Deferring Radiation Therapy in Patients With Epidermal Growth Factor Receptor-Mutant Non-Small Cell Lung Cancer Who Develop Brain Metastases. Int J Radiat Oncol Biol Phys 2016;95:673-679. doi: 10.1016/j.ijrobp.2016.01.037.

10. Kano H, Kondziolka D, Zorro O, Lobato-Polo J, Flickinger JC, Lunsford LD. The results of resection after stereotactic radiosurgery for brain metastases. J Neurosurg 2009;111:825-831. doi: 10.3171/2009.4.Jns09246.

11. Magnuson WJ, Lester-Coll NH, Wu AJ, Yang TJ, Lockney NA, Gerber NK , et al. Management of Brain Metastases in Tyrosine Kinase Inhibitor-Naïve Epidermal Growth Factor Receptor-Mutant Non-Small-Cell Lung Cancer: A Retrospective Multi-Institutional Analysis. J Clin Oncol 2017;35:1070-1077. doi: 10.1200/jco.2016.69.7144. 12. Soffietti R, Kocher M, Abacioglu UM, Villa S, Fauchon F, Baumert BG , et al. A European Organisation for Research and Treatment of Cancer phase III trial of adjuvant whole-brain radiotherapy versus observation in patients with one to three brain metastases from solid tumors after surgical resection or radiosurgery: quality-of-life results. J Clin Oncol 2013;31:65-72. doi: 10.1200/jco.2011.41.0639.